The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2023 | Efficacy and safety of lurbinectedin in elderly patients with relapsed SCLC
Sophie Cousin, MD, Institut Bergonié, Bordeaux, France, talks on a post hoc analysis evaluating the efficacy and safety of lurbinectedin in elderly patients with relapsed small cell lung cancer (SCLC). The study included patients from two trials, the Phase II basket trial (NCT02454972) and the Phase III ATLANTIS (NCT02566993) trial. Lurbinectedin demonstrated superiority over the standard of care in terms of efficacy, with higher response rates and longer duration of response and overall survival. Additionally, lurbinectedin showed a favorable safety profile with fewer associated hematological adverse events in comparison to the control arm. These findings suggest that lurbinectedin may be a promising treatment option for relapsed SCLC patients aged 65 years and older. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
In small cell lung cancer, there is sometimes a very old patient with comorbidity, and we were a little bit aware of the the toxicity of the molecule lurbinectedin, which is a very meaningful molecule with good objective response rate in small-cell lung cancer as second line treatment. So with our work, we we have conclude that elderly patient can receive safely the lurbinectedin without increase of the toxicities...
In small cell lung cancer, there is sometimes a very old patient with comorbidity, and we were a little bit aware of the the toxicity of the molecule lurbinectedin, which is a very meaningful molecule with good objective response rate in small-cell lung cancer as second line treatment. So with our work, we we have conclude that elderly patient can receive safely the lurbinectedin without increase of the toxicities. So that’s a good point because it’s a good molecule and we don’t want the elderly patient to be undertreated.
Read more...
